Investigation of the Therapeutic Efficacy of Codelivery of psiRNA–Vascular Endothelial Growth Factor and pIL‐4 into Chitosan Nanoparticles in the Breast Tumor Model. Issue 3 (19th December 2013)

• Record Type: Journal Article
• Authors: Şalva, Emine; Turan, Suna O.; Kabasakal, Levent; Alan, Saadet; Özkan, Naziye; Eren, Fatih; Akbuğa, Jülide
• Is Part Of: Journal of pharmaceutical sciences. Volume 103:Issue 3(2014:Mar.)
• Page Start: 785
• Page End: 795
• Publication Date: 2013-12-19
• Subjects: Pharmacy -- Periodicals; 615.1
• DOI: 10.1002/jps.23815
• Languages: English
• ISSNs: 0022-3549

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Angiogenesis has been known to increase tumor growth and for its metastatic potential in human tumors. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and is a promising therapeutic target for breast cancer. VEGF is an essential target for RNAi‐based gene therapy of breast cancer. Interleukin‐4 (IL‐4) may act as an anti‐angiogenic molecule that inhibits tumor growth and migration in rats. The purpose of the present study was to improve therapeutic efficacy in breast cancer with the codelivery of siRNA‐expressing plasmid targeting VEGF and IL‐4‐expressing plasmid encapsulating into chitosan nanoparticles (NPs). The codelivery of psiVEGF and pIL‐4 plasmids greatly enhanced <italic>in vitro</italic> and <italic>in vivo</italic> gene‐silencing efficiency. For the <italic>in vitro</italic> study, when psiVEGF and pIL‐4 into chitosan NPs were combined (81%), the gene‐silencing effect was higher than psiVEGF and pIL‐4 NPs alone. The <italic>in vivo</italic> study breast tumor model demonstrated that the administration of coencapsulation of psiVEGF and pIL‐4 into chitosan NPs caused an additive effect on breast tumor growth inhibition (97%), compared with containing NPs psiVEGF or pIL‐4 alone. These results indicate that chitosan NPs can be effectively used for the codelivery of pIL‐4 and siVEGF‐expressing plasmid in a combination therapy against breast cancer. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:785–795, 2014</p> </abstract>